|
⚲
|
| Keyboard |
| Schroder Adveq Management Luxembourg Sarl | |
|---|---|
| Firm | Schroders Capital Management US Inc |
| Address | 6C, Rue Gabriel Lippmann Munsbach, N4 L-5365 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Schroders Capital Management US Inc | |||||
| Schroders Capital Private Equity Europe VII SCS | 021-297598 | Executive Officer | 571.5 M of 684.7 M |
986.5 M | |
| Schroders Capital Private Equity Europe Direct II SCS | 021-280940 | Executive Officer | 220.7 M of 550.0 M |
319.4 M | |
| Schroders Capital Private Equity Global II SCS | 021-279595 | Executive Officer | 240.3 M of 570.6 M |
465.0 M | |
| Schroders Capital Private Equity Global Innovation IX SCS | 021-280941 | Executive Officer | 148.4 M of 500.0 M |
317.6 M | |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Decibel Therapeutics Inc DBTX
Common Stock
|
2021-02-17 | Conversion | 524,328 | ||
|
Decibel Therapeutics Inc DBTX
Common Stock
|
2021-02-17 | Conversion | 524,328 | ||
|
Decibel Therapeutics Inc DBTX
Series C Preferred Stock · derivative
|
2021-02-17 | Conversion | 6,625,001 | ||
|
Decibel Therapeutics Inc DBTX
Series C Preferred Stock · derivative
|
2021-02-17 | Conversion | 6,625,001 |